Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02880956 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT02880956: Completed Phase 2 study of Alzheimers Disease, sponsored by AbbVie.
NCT02880956 is a Phase 2 study of Alzheimers Disease that has completed, run by AbbVie. The registered enrollment target is 453 participants, below the 3,923-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02880956, a Phase 2 study of Alzheimers Disease, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
Primary Outcome
The CDR-SB is a numeric scale used to quantify the severity of symptoms of dementia. A qualified health professional assesses a participant's cognitive and functional performance in 6 areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The CDR scale gives a score from 0 to 3 for each of the 6 areas, with a lower value being desirable. The sum of these 6 areas, the CDR-SB score, can range from 0 to 18, with a lower value being desirabl
Conditions Studied
Interventions
- DRUG ABBV-8E12
- DRUG placebo for ABBV-8E12
Study Locations (20)
Florida
- Brain Matters Research /ID# 147796 - Delray Beach
- Neuropsychiatric Research Center of Southwest Florida /ID# 162332 - Fort Myers
- Mayo Clinic /ID# 151236 - Jacksonville
- Synexus Clinical Research US, Inc. /ID# 147804 - Orlando
- University of South Florida /ID# 151890 - Tampa
- Synexus Clinical Research US, Inc /ID# 151633 - The Villages
California
- Irvine Clinical Research /ID# 162331 - Irvine
- Ucsd /Id# 152467 - La Jolla
- Ray Dolby Brain Health Center /ID# 154965 - San Francisco
- Univ California, San Francisco /ID# 152053 - San Francisco
Georgia
- Emory Midtown Infectious Disease Clinic /ID# 151492 - Atlanta
- Atlanta Center for Medical Research /ID# 151550 - Atlanta
- NeuroStudies.net, LLC /ID# 152746 - Decatur
Illinois
- Great Lakes Clinical Trials /ID# 152754 - Chicago
- Advocate Lutheran General Hospital /ID# 152052 - Park Ridge
- Southern IL Univ School of Med /ID# 151769 - Springfield
Arizona
- Banner University of Arizona Medical Center Phoenix /ID# 151536 - Phoenix
- Banner Sun Health Res Inst /ID# 151895 - Sun City
Indiana
- Indiana University /ID# 151861 - Indianapolis
Kansas
- University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554 - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 2 |
What the finished NCT02880956 record still lists
NCT02880956 is an interventional study that assigns participants to a tested intervention. The registered 453 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which ABBV-8E12 is the first listed.
NCT02880956 names 20 study sites across 7 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02880956 about?
NCT02880956 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease". This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
What is the current status of trial NCT02880956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 453 participants. The study started on 2017-01-26. Estimated completion is 2021-07-28.
What conditions does trial NCT02880956 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT02880956?
The interventions under investigation include: ABBV-8E12 (DRUG), placebo for ABBV-8E12 (DRUG).
Who is sponsoring clinical trial NCT02880956?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02880956 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02880956's enrollment target sits among peer trials
453 31st of 147 higher than 117 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI